The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials

The aim of this paper is to evaluate the efficacy and safety of Rebamipide (REB) ophthalmic suspension in dry eye disease (DED). A systematic review that only included full-length randomized controlled studies (RCTs) reporting the effects of REB ophthalmic suspension in three databases, PubMed, Scopus and Web of Science, was performed according to the PRISMA statement. The Cochrane risk of bias tool was used to analyze the quality of the studies selected. A total of seven studies were included in this systematic review. Although the overall risk of bias was low, most studies were sponsored by the manufacturer. REB ophthalmic suspension treatment achieved higher improvement than the control group in all reported variables. The mean differences between both groups were in favor of the REB group and were as follows: dry eye-related quality of life score (DEQS) -3.5 +/- 2.9 points, tear film break-up time (TBUT) of 0.7 +/- 0.6 s, Schirmer test (ST) without anesthesia of 0.3 +/- 0.6 mm and total corneal fluorescein staining (tCFS) of -1.2 +/- 0.7 points. Adverse events (AEs) were 5.2 +/- 7.6% superior in the REB group, with an overall compliance > 95%. Therefore, REB ophthalmic suspension is a safe and effective treatment that could be recommended in patients with DED.

Automated summary

This paper evaluates the efficacy and safety of Rebamipide (REB) ophthalmic suspension in the treatment of dry eye disease (DED). The results show that REB ophthalmic suspension significantly improves dry eye-related quality of life score, tear film break-up time, Schirmer test, and total corneal fluorescein staining. The occurrence of adverse events is low and overall compliance is high.